US Patent

US11919907 — Deuterated JAK inhibitor and uses thereof

Method of Use · Assigned to Sun Pharmaceutical Industries Inc · Expires 2041-05-21 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a deuterated JAK inhibitor, specifically deuteruxolitinib phosphate, for use in treating hair loss disorders.

USPTO Abstract

Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3976`	—	deuruxolitinib-phosphate

Patent Metadata

Patent number: US11919907
Jurisdiction: US
Classification: Method of Use
Expires: 2041-05-21
Drug substance claim: No
Drug product claim: Yes
Assignee: Sun Pharmaceutical Industries Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.